NTRK2 Fusion | Cancer Search

mutation class

Gene Rearrangement

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

104 sites for NCT04589845

AKT1 Mutation, +39 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +8 more drugs

immunotherapy, +1 more type

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

127 sites for NCT02568267

ALK Fusion, +4 more biomarkers

Malignant Solid Tumor

entrectinib

targeted therapy

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

119 sites for NCT02576431

NTRK1 Fusion, +2 more biomarkers

Biliary Tract Carcinoma, +12 more conditions

larotrectinib

targeted therapy

Genetic Testing in Guiding Treatment for Patients With Brain Metastases